NCT00363701

Brief Summary

The primary purpose of the study is to determine the effect of esomeprazole compared to placebo in patients from general practice who have previously been treated with proton-pump-inhibitors (PPI) and who have no upper endoscopic findings.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Aug 2006

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

August 14, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 15, 2006

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2008

Completed
Last Updated

August 15, 2006

Status Verified

August 1, 2006

First QC Date

August 14, 2006

Last Update Submit

August 14, 2006

Conditions

Keywords

Protonpumpinhibitorswithdrawallongterm treatmentdyspepsiafunctional dyspepsiagastrooesophageal refluxupper endoscopy

Outcome Measures

Primary Outcomes (1)

  • Comparison of the effect of treatment in one week with esomeprazole and placebo measured as symptomscore in patientdiary.

Secondary Outcomes (6)

  • Fraction of patients who are willing to withdraw treatment with PPI

  • Fraction of patients who experience symptoms after withdrawal of treatment.

  • Description of endoscopic findings in patients who have previously been treated with PPI long-term and who after withdrawal are symptomatic

  • Length of time from withdrawal till symptoms arise

  • Correlation between levels of gastrin and CgA and time till symptoms arise

  • +1 more secondary outcomes

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Treatment with PPI in at least 4 months out of the preceding 12.
  • Age above 18 years

You may not qualify if:

  • Erosive Esophagitis
  • PPI-treatment as prophylaxis against gastrointestinal bleeding
  • PPI-treatment as prophylaxis against ulcers
  • PPI-treatment as prophylaxis because of NSAID-treatment
  • Pregnant or lactating women
  • Previous upper GI surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of gastroenterology, Glostrup University Hospital

Glostrup Municipality, 2600, Denmark

RECRUITING

MeSH Terms

Conditions

DyspepsiaUlcerGastroesophageal Reflux

Interventions

Esomeprazole

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic ProcessesEsophageal Motility DisordersDeglutition DisordersEsophageal DiseasesGastrointestinal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Omeprazole2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Peter Bytzer, ass. professor, ph.d

    Glostrup University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 14, 2006

First Posted

August 15, 2006

Study Start

August 1, 2006

Study Completion

February 1, 2008

Last Updated

August 15, 2006

Record last verified: 2006-08

Locations